JP2016523974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523974A5 JP2016523974A5 JP2016525472A JP2016525472A JP2016523974A5 JP 2016523974 A5 JP2016523974 A5 JP 2016523974A5 JP 2016525472 A JP2016525472 A JP 2016525472A JP 2016525472 A JP2016525472 A JP 2016525472A JP 2016523974 A5 JP2016523974 A5 JP 2016523974A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- alkoxy
- aryl
- membered monocyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001475 halogen functional group Chemical group 0.000 claims 14
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 13
- 125000003107 substituted aryl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 4
- -1 1-hydroxybenzyl Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims 2
- 125000000169 tricyclic heterocycle group Chemical group 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 1
- 229940113303 Indoleamine 2,3-dioxygenase inhibitor Drugs 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000004999 nitroaryl group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 229960004854 viral vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361844897P | 2013-07-11 | 2013-07-11 | |
| US61/844,897 | 2013-07-11 | ||
| PCT/US2014/046066 WO2015006520A1 (en) | 2013-07-11 | 2014-07-10 | Ido inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523974A JP2016523974A (ja) | 2016-08-12 |
| JP2016523974A5 true JP2016523974A5 (cg-RX-API-DMAC7.html) | 2017-08-17 |
| JP6478991B2 JP6478991B2 (ja) | 2019-03-06 |
Family
ID=51263510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525472A Expired - Fee Related JP6478991B2 (ja) | 2013-07-11 | 2014-07-10 | Ｉｄｏ阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9895330B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3019488B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6478991B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105517999B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2917964A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201690152A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2707961T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX366875B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015006520A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2694640T3 (cg-RX-API-DMAC7.html) | 2011-04-15 | 2018-03-17 | ||
| AU2014235750B2 (en) * | 2013-03-15 | 2018-05-17 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase (IDO) |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| CN103570727B (zh) | 2013-11-12 | 2015-08-19 | 复旦大学 | 一种n-苄基色胺酮衍生物及其制备方法和应用 |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2016141188A1 (en) | 2015-03-03 | 2016-09-09 | Mayo Foundation For Medical Education And Research | Compounds for modulating mitochondrial function |
| EP3313824A1 (en) | 2015-06-26 | 2018-05-02 | Bristol-Myers Squibb Company | Ido inhibitors |
| CA2992016C (en) | 2015-07-24 | 2019-10-22 | Newlink Genetics Corporation | Salts and prodrugs of 1-methyl-d-tryptophan |
| RU2018112830A (ru) * | 2015-09-24 | 2019-10-24 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Модуляторы индоламин-2,3-диоксигеназы |
| CA2998826A1 (en) * | 2015-09-24 | 2017-03-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Modulators of indoleamine 2,3-dioxygenase |
| US10980807B2 (en) | 2016-02-09 | 2021-04-20 | Inventisbio Llc | Inhibitor of indoleamine-2,3-dioxygenase (IDO) |
| US11752131B2 (en) | 2016-02-19 | 2023-09-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of obesity |
| JP2019516681A (ja) | 2016-05-04 | 2019-06-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法 |
| EP3452451A4 (en) | 2016-05-04 | 2019-11-13 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
| JP2019522627A (ja) | 2016-05-04 | 2019-08-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法 |
| KR20190006186A (ko) * | 2016-05-12 | 2019-01-17 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 인돌아민 2,3-디옥시게나제의 조정자 |
| JP2019528300A (ja) | 2016-08-26 | 2019-10-10 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法 |
| EP3515914A4 (en) | 2016-09-24 | 2020-04-15 | BeiGene, Ltd. | NEW IMIDAZO [1,5-A] PYRIDINES SUBSTITUTED IN POSITION 5 OR 8 AS INDOLEAMINE AND / OR TRYPTOPHANE 2,3-DIOXYGENASES |
| CA3037387A1 (en) | 2016-10-13 | 2018-04-19 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
| WO2018116108A1 (en) * | 2016-12-20 | 2018-06-28 | Glaxosmithkline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| SG10201911243WA (en) | 2016-12-22 | 2020-02-27 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
| CN109180649B (zh) * | 2017-08-18 | 2021-03-12 | 四川百利药业有限责任公司 | 一种含吲哚环的ido抑制剂及其制备方法 |
| WO2019141095A1 (zh) * | 2018-01-19 | 2019-07-25 | 四川科伦博泰生物医药股份有限公司 | 脒类和胍类衍生物、其制备方法及其在医药上的应用 |
| US12059420B2 (en) * | 2018-07-23 | 2024-08-13 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| CN111153850B (zh) * | 2020-01-17 | 2021-08-13 | 中国药科大学 | 吲哚类化合物、其制备方法和药物组合物与用途 |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| MX2023010371A (es) | 2021-03-05 | 2024-02-12 | Univ Basel | Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb. |
| CN113861176B (zh) * | 2021-09-28 | 2023-11-03 | 北京凯因格领生物技术有限公司 | 一种黄病毒抑制剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060006953A (ko) | 2003-04-30 | 2006-01-20 | 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 | 치환된 카르복실산 |
| ES2540561T3 (es) * | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| US7951829B2 (en) * | 2006-05-03 | 2011-05-31 | Janssen Pharmaceutica Nv | Benzimidazole modulators of VR1 |
| WO2008136378A1 (ja) * | 2007-04-27 | 2008-11-13 | Toyama Chemical Co., Ltd. | 新規なスルホンアミド誘導体またはその塩 |
| US8067409B2 (en) * | 2007-11-27 | 2011-11-29 | Abbott Laboratories | Protein kinase inhibitors |
| ES2601226T3 (es) * | 2009-10-28 | 2017-02-14 | Newlink Genetics Corporation | Derivados de imidazol como inhibidores de IDO |
| EP2441755A1 (en) * | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
| AU2014235750B2 (en) * | 2013-03-15 | 2018-05-17 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase (IDO) |
| CA2907178A1 (en) * | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Ido inhibitors |
| MX2015017486A (es) * | 2013-07-01 | 2016-03-21 | Squibb Bristol Myers Co | Inhibidores de indolamina 2,3-dioxigenasa (dio). |
| WO2015031295A1 (en) * | 2013-08-27 | 2015-03-05 | Bristol-Myers Squibb Company | Ido inhibitors |
-
2014
- 2014-07-10 CN CN201480049850.9A patent/CN105517999B/zh not_active Expired - Fee Related
- 2014-07-10 ES ES14747209T patent/ES2707961T3/es active Active
- 2014-07-10 US US14/903,091 patent/US9895330B2/en active Active
- 2014-07-10 EP EP14747209.6A patent/EP3019488B1/en not_active Not-in-force
- 2014-07-10 EA EA201690152A patent/EA201690152A1/ru unknown
- 2014-07-10 MX MX2016000295A patent/MX366875B/es active IP Right Grant
- 2014-07-10 CA CA2917964A patent/CA2917964A1/en not_active Abandoned
- 2014-07-10 JP JP2016525472A patent/JP6478991B2/ja not_active Expired - Fee Related
- 2014-07-10 WO PCT/US2014/046066 patent/WO2015006520A1/en not_active Ceased